세포 및 유전자 치료 임상시험 서비스 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cell & gene therapy clinical trial services market size is expected to reach USD 46.58 Billion in 2034 from USD 12.87 Billion in 2025, growing at a CAGR of 15.36% during 2026-2034.The global cell and gene therapy clinical trial services market is expanding rapidly due to increasing research in advanced biopharmaceutical treatments. Cell and gene therapies offer promising solutions for treating complex diseases such as cancer, genetic disorders, and rare conditions. As pharmaceutical companies invest heavily in these innovative therapies, the demand for specialized clinical trial services is rising.

Clinical research organizations are providing expertise in trial design, patient recruitment, regulatory compliance, and data management for complex therapy studies. These services are essential for ensuring the safety, effectiveness, and regulatory approval of new therapies. The increasing number of ongoing clinical trials in regenerative medicine is significantly supporting market growth.

Looking ahead, the market is expected to witness strong expansion as biotechnology research continues to advance. Governments and private investors are increasing funding for gene therapy development and clinical research programs. As more cell and gene therapy products move toward commercialization, the demand for specialized clinical trial services will continue to grow.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Indication

• Oncology
• Cardiology
• CNS
• Musculoskeletal
• Infectious Diseases
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Ophthalmology
• Hematology
• Gastroenterology
• Others

COMPANIES PROFILED

• IQVIA, Labcorp, ICON, Parexel, Charles River Laboratories, Thermo Fisher Scientific, WuXi AppTec, Medpace, PPD/Thermo Fisher, Fortrea, Syneos Health, Worldwide Clinical Trials, Premier Research, Pharm-Olam, Precision for Medicine, Advanced Clinical, Veristat, Allucent, NAMSA, CTI Clinical Trial and Consulting Services

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET: BY PHASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Phase
• 4.2. Phase I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phase II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Phase III Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phase IV Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Endocrine, Metabolic, Genetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Immunology & Inflammation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Gastroenterology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Phase
  • 6.2.2 By Indication
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Phase
  • 6.3.2 By Indication
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Phase
  • 6.4.2 By Indication
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Phase
  • 6.5.2 By Indication
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Phase
  • 6.6.2 By Indication
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 IQVIA
  • 8.2.2 Labcorp
  • 8.2.3 ICON
  • 8.2.4 Parexel
  • 8.2.5 Charles River Laboratories
  • 8.2.6 Thermo Fisher Scientific
  • 8.2.7 WuXi AppTec
  • 8.2.8 Medpace
  • 8.2.9 PPD/Thermo Fisher
  • 8.2.10 Fortrea
  • 8.2.11 Syneos Health
  • 8.2.12 Worldwide Clinical Trials
  • 8.2.13 Premier Research
  • 8.2.14 Pharm-Olam
  • 8.2.15 Precision For Medicine
  • 8.2.16 Advanced Clinical
  • 8.2.17 Veristat
  • 8.2.18 Allucent
  • 8.2.19 NAMSA
  • 8.2.20 CTI Clinical Trial And Consulting Services